Establishing a Competitive Advantage and Securing Sales in the Domestic Prescription Pharmaceutical Market

「Revenue from the pharmaceutical business was ¥77,950 million, up 3.5% from the previous consolidated fiscal year. Revenue increased, driven by growth in sales of Beova, a treatment for overactive bladder; Tabuneos, a treatment for microscopic polyangiitis and granulomatosis with polyangiitis; Korsuva, a treatment for pruritus in dialysis patients; and Tavalis, a treatment for persistent and chronic immune thrombocytopenia.」

「Pharmaceutical business net sales were ¥38,347 million, up 4.7% year on year. Net sales increased due to growth in sales of Beova, the overactive bladder treatment; Tabneus, the treatment for microscopic polyangiitis and granulomatosis with polyangiitis; Korsuva, the treatment for pruritus in dialysis patients; and Tavalis, the treatment for chronic idiopathic thrombocytopenic purpura.」

「Pharmaceutical business net sales were ¥75,299 million, up 18.9% from the previous fiscal year. In addition to the overactive bladder treatment Beova Tablets, sales grew for the 4 products launched during the period of the medium-term management plan PEGASUS: Tabneus Capsules, a treatment for microscopic polyangiitis and granulomatosis with polyangiitis; Korsuva Intravenous Syringe for Hemodialysis, a treatment for pruritus in dialysis patients; Tavalis Tablets, a treatment for chronic idiopathic thrombocytopenic purpura; and Kalogra Tablets, an ulcerative colitis treatment. Overseas licensing revenue and other income also increased, resulting in higher net sales.」

「Pharmaceutical business net sales were ¥36,633 million, up 19.1% year on year. In addition to the overactive bladder treatment Beova Tablets, sales grew for the 4 products launched during the period of the medium-term management plan PEGASUS: the ulcerative colitis treatment Kalogra Tablets, the treatment for microscopic polyangiitis and granulomatosis with polyangiitis Tabneus Capsules, the chronic idiopathic thrombocytopenic purpura treatment Tavalis Tablets, and Korsuva Intravenous Syringe for Hemodialysis, a treatment for pruritus in dialysis patients. Technical fee revenue and other income also increased, resulting in higher net sales.」

「Pharmaceutical business net sales were ¥63,348 million, up 12.6% from the previous fiscal year. The Company newly launched Tavalis Tablets, a treatment for chronic idiopathic thrombocytopenic purpura, in April 2023 and Korsuva Intravenous Syringe for Hemodialysis, a treatment for pruritus in dialysis patients, in December of the same year.」

「Pharmaceutical business net sales were ¥48,616 million, up 11.4% year on year. In domestic pharmaceuticals, sales of Tabneus Capsules, a treatment for microscopic polyangiitis and granulomatosis with polyangiitis, and Kalogra Tablets, an ulcerative colitis treatment, both newly launched in fiscal 2022, continued to grow. Sales of the overactive bladder treatment Beova Tablets and the chronic idiopathic thrombocytopenic purpura treatment Tavalis Tablets, newly launched in April 2023, as well as co-promotion fees, increased. In addition, the Company newly launched Korsuva Intravenous Syringe for Hemodialysis, a treatment for pruritus in dialysis patients jointly developed with Maruishi Pharmaceutical Co., Ltd., in December 2023.」

「Pharmaceutical business net sales were ¥30,765 million, up 10.1% year on year. In domestic pharmaceuticals, sales of the ulcerative colitis treatment Kalogra Tablets and the treatment for microscopic polyangiitis and granulomatosis with polyangiitis Tabneus Capsules, both newly launched last fiscal year, continued to grow. Sales of the overactive bladder treatment Beova Tablets, the chronic idiopathic thrombocytopenic purpura treatment Tavalis Tablets, newly launched in April this year, and co-promotion fees increased, resulting in higher net sales.」

「Pharmaceutical business net sales were ¥16,065 million, up 15.4% year on year. In domestic pharmaceuticals, sales of the ulcerative colitis treatment Kalogra Tablets and the treatment for microscopic polyangiitis and granulomatosis with polyangiitis Tabneus Capsules, both newly launched last fiscal year, continued to grow. Sales of the overactive bladder treatment Beova Tablets and the chronic idiopathic thrombocytopenic purpura treatment Tavalis Tablets, newly launched in April this year, as well as co-promotion fees, increased. Export sales and supply revenue from domestic marketing partners also increased, resulting in higher net sales.」

「Pharmaceutical business net sales were ¥43,641 million, up 4.1% year on year. Amid the COVID-19 pandemic, the Company promoted hybrid medical information activities that effectively combined conventional face-to-face meetings with various digital content, and sales of products including the overactive bladder treatment Beova Tablets and the renal anemia treatment darbepoetin alfa BS injection JCR increased. In addition, net sales increased due to higher technical fee revenue, export sales and co-promotion fees.」

「Pharmaceutical business net sales were ¥27,946 million, up 3.6% year on year. Amid the COVID-19 pandemic, the Company promoted hybrid medical information activities that effectively combined conventional face-to-face meetings with various digital content, and sales of products including the overactive bladder treatment Beova Tablets and the renal anemia treatment darbepoetin alfa BS injection JCR increased. In addition, net sales increased due to higher export sales and co-promotion fees. Kalogra Tablets, an ulcerative colitis treatment jointly developed with EA Pharma Co., Ltd., was newly launched in May this year, and Tabneus Capsules, a treatment for microscopic polyangiitis and granulomatosis with polyangiitis, was newly launched in June.」

「Pharmaceutical business net sales were ¥13,915 million, down 0.1% year on year. Amid the COVID-19 pandemic, the Company promoted hybrid medical information activities that effectively combined conventional face-to-face meetings with various digital content, and sales of products including the overactive bladder treatment Beova Tablets and the renal anemia treatment darbepoetin alfa BS injection JCR increased. However, net sales declined due in part to the impact of the drug price revision implemented in April this year and a decrease in export sales. Kalogra Tablets, an ulcerative colitis treatment jointly developed with EA Pharma Co., Ltd., was newly launched in May this year, and Tabneus Capsules, a treatment for microscopic polyangiitis and granulomatosis with polyangiitis, was newly launched in June.」

「As a result, pharmaceutical business net sales decreased by ¥2,260 million, or 4.0%, from the previous fiscal year to ¥54,147 million. Upasita Intravenous Syringe for Hemodialysis, a treatment for secondary hyperparathyroidism for which the Company had signed a co-promotion agreement with Sanwa Kagaku Kenkyusho Co., Ltd. in Japan, was newly launched by the company in August last year. In addition, Kalogra Tablets 120mg, an ulcerative colitis treatment jointly developed with EA Pharma Co., Ltd. and approved for manufacture and marketing by the company in March this year, was newly launched in May. Tabneus Capsules 10mg, a treatment for microscopic polyangiitis and granulomatosis with polyangiitis for which the Company obtained manufacturing and marketing approval in September last year, was newly launched in June.」

「Pharmaceutical business net sales were ¥26,968 million, down 5.0% year on year. Amid medical information activities conducted with sufficient attention to infection prevention amid the COVID-19 pandemic, as in the previous fiscal year, sales of products including the overactive bladder treatment Beova Tablets, Minirin Melt OD Tablets 25µg/50µg and Minirin Melt OD Tablets 60µg/120µg/240µg, treatments for nocturia caused by nocturnal polyuria in men, and desmopressin products increased. However, net sales declined due in part to the impact of the drug price revision implemented in April this year and a decrease in export sales. Upasita Intravenous Syringe for Hemodialysis, a treatment for secondary hyperparathyroidism for which the Company had signed a co-promotion agreement with Sanwa Kagaku Kenkyusho Co., Ltd. in Japan, was newly launched by the company in August this year.」

「Pharmaceutical business net sales were ¥13,924 million, down 5.3% year on year. Amid medical information activities conducted with sufficient attention to infection prevention amid the COVID-19 pandemic, as in the previous fiscal year, sales of products including the overactive bladder treatment Beova Tablets, Minirin Melt OD Tablets 25µg/50µg and Minirin Melt OD Tablets 60µg/120µg/240µg, treatments for nocturia caused by nocturnal polyuria in men, and desmopressin products increased. However, net sales declined due in part to the impact of the drug price revision implemented in April this year and a decrease in export sales. In June this year, following Sanwa Kagaku Kenkyusho Co., Ltd.'s approval of the secondary hyperparathyroidism treatment Upasita Intravenous Syringe for Hemodialysis in the same month, the Company signed a co-promotion agreement with the company in Japan and both companies have begun medical information activities.」

「Pharmaceutical business net sales were ¥44,463 million, up 10.4% year on year. Medical information activities were limited due to the impact of COVID-19, but sales of products including the renal anemia treatment darbepoetin alfa BS injection JCR, the overactive bladder treatment Beova Tablets, and the hyperphosphatemia treatments P-TOL Chewable Tablets and P-TOL Granules in Sachets increased. In addition, sales increased due in part to contributions from products transferred for marketing in April last year, including Minirin Melt OD Tablets 25µg/50µg, Minirin Melt OD Tablets 60µg/120µg/240µg, desmopressin products and the diabetes treatment Marizev Tablets.」

「Pharmaceutical business net sales were ¥28,394 million, up 6.9% year on year. Medical information activities were limited due to the impact of COVID-19, but sales of products including the overactive bladder treatment Beova Tablets, the renal anemia treatment darbepoetin alfa BS injection JCR, and the hyperphosphatemia treatments P-TOL Chewable Tablets and P-TOL Granules in Sachets increased. In addition, sales increased due in part to contributions from products transferred in April this year, including Minirin Melt OD Tablets 25µg/50µg, a treatment for nocturia caused by nocturnal polyuria in men; Minirin Melt OD Tablets 60µg/120µg/240µg, treatments for nocturnal enuresis and central diabetes insipidus; desmopressin products; and the diabetes treatment Marizev Tablets.」

「Revenue from the pharmaceutical business was ¥14,700 million, up 4.1% year on year. Although medical information activities were limited due to the impact of COVID-19, revenue increased due to higher sales of products including the overactive bladder treatment Beova Tablets, the renal anemia treatment Darbepoetin Alfa BS Injection JCR, and the hyperphosphatemia treatments Pitol Chewable Tablets and Pitol Granules in Sachets, as well as contributions from Minirin Melt OD Tablets 25 µg/50 µg, a treatment for nocturia caused by nocturnal polyuria in men, Minirin Melt OD Tablets 60 µg/120 µg/240 µg and desmopressin products, treatments for enuresis and central diabetes insipidus, and the diabetes treatment Marizev Tablets, whose sales were transferred in April this year.」

「As a result, pharmaceutical business net sales decreased by ¥10,212 million, or 16.6%, from the previous fiscal year to ¥51,308 million. In addition, the renal anemia treatment darbepoetin alfa BS injection JCR, jointly developed with JCR Pharmaceuticals Co., Ltd., has been marketed since November last year.」

「Pharmaceutical business net sales were ¥40,288 million, down 15.5% year on year. Sales of products including the overactive bladder treatment Beova Tablets, the hyperphosphatemia treatments P-TOL Chewable Tablets and P-TOL Granules in Sachets, and the diabetes treatment GUBLES Combination Tablets and GUBLES Combination OD Tablets, which was newly launched in June last year as an additional dosage form, increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due to lower sales following the launch of generic versions of the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets.」

「Pharmaceutical business net sales were ¥26,557 million, down 11.4% year on year. Sales of products including the hyperphosphatemia treatments P-TOL Chewable Tablets and P-TOL Granules in Sachets, the overactive bladder treatment Beova Tablets, the diabetes treatment GUBLES Combination Tablets and the newly launched GUBLES Combination OD Tablets launched in June this year as an additional dosage form increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due to lower sales following the launch of generic versions of the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets. In addition, the Company signed a co-promotion agreement with Ferring Pharmaceuticals Co., Ltd. in June this year for Minirin Melt OD Tablets 25µg and 50µg, treatments for nocturia caused by nocturnal polyuria in men. The products were newly launched in September, and both companies are conducting medical information activities.」

「Pharmaceutical business net sales were ¥14,123 million, down 9.0% year on year. Sales of products including the hyperphosphatemia treatments P-TOL Chewable Tablets and P-TOL Granules in Sachets, the overactive bladder treatment Beova Tablets, the diabetes treatment GUBLES Combination Tablets and the newly launched GUBLES Combination OD Tablets launched in June this year as an additional dosage form increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due to lower sales following the launch of generic versions of the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, as well as a decrease in technical fee revenue.」

「Although the patents for the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets expired in December last year, sales of Urief Tablets and Urief OD Tablets, the hyperphosphatemia treatment P-TOL Chewable Tablets, and the ulcerative colitis treatment Rectabul 2mg Rectal Foam 14 Doses increased, mainly as a result of promoting active medical information activities for core products. However, due in part to the impact of the drug price revision implemented in April last year and a decrease in technical fee revenue, sales decreased by ¥2,371 million, or 3.7%, from the previous fiscal year to ¥61,520 million.」

「Pharmaceutical business net sales were ¥4,767.1 million, down 4.3% year on year. Sales of products including the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, the hyperphosphatemia treatment P-TOL Chewable Tablets, and the ulcerative colitis treatment Rectabul 2mg Rectal Foam 14 Doses increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due in part to the impact of the drug price revision implemented in April last year and a decrease in technical fee revenue.」

「Pharmaceutical business net sales were ¥2,998.5 million, down 7.2% year on year. Sales of products including the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, the hyperphosphatemia treatment P-TOL Chewable Tablets, and the ulcerative colitis treatment Rectabul 2mg Rectal Foam 14 Doses, which was newly launched in December last year, increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due in part to the impact of the drug price revision implemented in April this year and a decrease in technical fee revenue.」

「Pharmaceutical business net sales were ¥1,552.6 million, down 6.8% year on year. Sales of products including the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, the hyperphosphatemia treatment P-TOL Chewable Tablets, and the ulcerative colitis treatment Rectabul 2mg Rectal Foam 14 Doses, which was newly launched in December last year, increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due in part to the impact of the drug price revision implemented in April this year and a decrease in technical fee revenue.」

「Pharmaceutical business net sales increased by ¥243.6 million, or 4.0%, from the previous fiscal year to ¥6,389.1 million, due in part to higher sales of products including the hyperphosphatemia treatments P-TOL Chewable Tablets, Urief Tablets and Urief OD Tablets, and the renal anemia treatment Epoetin Alfa BS Injection JCR, as well as increases in export sales and technical fee revenue.」

「Pharmaceutical business net sales were ¥4,983 million, up 5.3% year on year. Sales of long-listed products and others declined, but sales of products including the hyperphosphatemia treatment P-TOL Chewable Tablets, the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, and the diabetes treatment GUBLES Combination Tablets increased, mainly as a result of promoting active medical information activities for core products. In addition, export sales and technical fee revenue increased, resulting in higher net sales.」

「Pharmaceutical business net sales were ¥3,229 million, up 5.9% year on year. Sales of long-listed products and others declined, but sales of products including the hyperphosphatemia treatment P-TOL Chewable Tablets, the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, and the diabetes treatment GUBLES Combination Tablets increased, mainly as a result of promoting active medical information activities for core products. In addition, export sales and technical fee revenue increased, resulting in higher net sales.」

「Pharmaceutical business net sales were ¥1,665 million, up 4.9% year on year. Sales of long-listed products and others declined, but sales of products including the hyperphosphatemia treatment P-TOL Chewable Tablets, the dysuria treatments for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, and the diabetes treatment GUBLES Combination Tablets increased, mainly as a result of promoting active medical information activities for core products. In addition, export sales and technical fee revenue increased, resulting in higher net sales.」

「Pharmaceutical business net sales were ¥6,145 million, down 0.6% from the previous fiscal year. Sales of products including the hyperphosphatemia treatment P-TOL Chewable Tablets, the dysuria treatment for benign prostatic hyperplasia Urief Tablets and Urief OD Tablets, and the diabetes treatments GUBLES Combination Tablets, Glufast Tablets and Glufast OD Tablets increased, mainly as a result of promoting active medical information activities for core products. However, net sales declined due in part to decreases in technical fee revenue and supply revenue from domestic marketing partners.」

「Pharmaceutical business sales amounted to ¥47.301 billion, down 1.3% year on year. In December last year, we entered into a co-promotion agreement in Japan with Aspen Japan Co., Ltd. for Imuran Tablets, an immunosuppressant manufactured and marketed by Aspen Japan, and began medical information activities in January this year.」

「Pharmaceutical business sales amounted to ¥30.507 billion, up 1.6% year on year. Sales increased partly because, in addition to sales of P-Tol Chewable Tablets, a treatment for hyperphosphatemia launched last November, sales of Ureef Tablets and Ureef OD Tablets, treatments for urinary disorders associated with benign prostatic hyperplasia, and Gurbece Combination Tablets and Glufast Tablets, diabetes treatments, increased as a result of active medical information activities for core products. We also launched Glufast OD Tablets, a diabetes treatment, in June this year.」

「Pharmaceutical business sales amounted to ¥15.882 billion, up 4.2% year on year. Sales increased partly because we pursued active medical information activities for core products, including Ureef Tablets and Ureef OD Tablets, treatments for urinary disorders associated with benign prostatic hyperplasia; Gurbece Combination Tablets and Glufast Tablets, diabetes treatments; and P-Tol Chewable Tablets, a treatment for hyperphosphatemia launched last November. We also launched Glufast OD Tablets, a diabetes treatment, in June this year.」

「We will concentrate sales resources on promotional activities for core products, including patented products such as Ureef, Glufast, Gurbece and P-Tol, with the aim of maximizing domestic prescription pharmaceutical sales at an early stage.」